Search
On November 1, 2023, Candice Kline will speak during the Financial Poise Webinar RESTRUCTURING, INSOLVENCY & TROUBLED COMPANIES 2023. The topic which she will speak on is "Bad Debtor Owes Me Money."
PCI, in partnership with Penn Medicine, is pleased to co-host a commercialization speaker series geared toward Penn Medicine faculty, researchers and students. Each session will feature an expert guest speaker as well as time for questions and discussion. The first session will discuss the latest...
Matt Kohel will participate as speaker during the Responsible AI in Intelligence Analysis conference at Georgetown University in Washington, D.C. Matt will speak on a panel titled AI Governance, Privacy and Civil Liberties Compliance .
Developing a Corporate AI Policy Join Association of Corporate Counsel, along with inside and outside counsel presenters, as they discuss implementing best practices and responsible use policies to manage the risk of utilizing AI in the workplace. Speakers : Matthew Kohel, Partner, Intellectual...
Since Elon Musk announced his decision to remove the iconic bird logo and adopt "X", as Twitter's new logo (the "X Logo"), the rebranding decision has been the talk of the town. The rollout has prompted a barrage of reactions and has many questioning whether the change will attract legal hurdles...
A recently filed class action lawsuit raises more legal challenges to providers of generative artificial intelligence (AI) tools that are used to create content. The suit cautions that a doomsday scenario is approaching and alleges a host of privacy and other violations occurring along the way. What...
Welcome to Saul Ewing’s Public Companies Quarterly Update series. Our intent is to, on a quarterly basis, highlight important legal developments of which we think public companies should be aware. This edition is related to developments during the second quarter of 2023. If you would like to discuss...
On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi , 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...